The authors must pay all page and color fees. ASBMB will consider requests for waiver of publication charges if research funds are not available for publication costs. Waiver requests must be made at the time of submission and the request must be co-signed by an institutional official certifying that the authors do not have research funds available for publication costs.
Another group of cancer therapeutic MAbs are the immunoconjugates. These MAbs, which are sometimes called immunotoxins or antibody-drug conjugates, consist of an antibody attached to a cell-killing substance, such as a plant or bacterial toxin, a chemotherapy drug, or a radioactive molecule. The antibody latches onto its specific antigen on the surface of a cancer cell, and the cell-killing substance is taken up by the cell. FDA-approved conjugated MAbs that work this way include 90 Y- ibritumomab tiuxetan , which targets the CD20 antigen to deliver radioactive yttrium -90 to B-cell non-Hodgkin lymphoma cells, and ado-trastuzumab emtansine , which targets the HER-2 molecule to deliver the drug DM1, which inhibits cell proliferation, to HER-2 expressing metastatic breast cancer cells.
The best little site that helps you understand word usage with examples.
Clostridium perfringens episilon toxin
Related by blood, as in a child's biological parents.